Your AI-Trained Oncology Knowledge Connection!

Enriqueta Felip, MD, PhD

home / authors / enriqueta-felip-md-phd

Enriqueta Felip, MD, PhD, is from the Universitat Autònoma de Barcelona, Spain, section chief at the Vall d'Hebron University Hospital, head of the Vall d' Hebron Institute of Oncology's thoracic tumors group.

Articles

SC Pembrolizumab in NSCLC May Boost Patient Experience, Efficiency

May 8th 2025

Enriqueta Felip, MD, PhD, discusses how results from the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab vs intravenous pembrolizumab, plus chemotherapy, for the treatment of metastatic NSCLC may impact patient experience and clinical workflow.

SC Pembrolizumab Noninferior to IV in NSCLC: Phase 3 Trial Results

Enriqueta Felip, MD, PhD

April 20th 2025

Enriqueta Felip, MD, PhD, discusses the 3475A-D77 trial of subcutaneous pembrolizumab vs intravenous pembrolizumab plus chemotherapy in metastatic NSCLC.

Behind the Phase 3 3475A-D77 Trial of SC Pembrolizumab in NSCLC

Enriqueta Felip, MD, PhD

April 14th 2025

Enriqueta Felip, MD, PhD, discusses the design of the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab in metastatic NSCLC.

Phase 3 Trial Evaluates SC Pembrolizumab vs IV in NSCLC

Enriqueta Felip, MD, PhD

April 5th 2025

Enriqueta Felip, MD, PhD, discusses the phase 3 3475A-D77 study of subcutaneous pembrolizumab plus chemotherapy in metastatic non–small cell lung cancer.